Holen Sie sich die Stockscreener-App
3.12
1.30%
0.04
Handel nachbörslich:
3.13
0.010
+0.32%
Schlusskurs vom Vortag:
$3.08
Offen:
$3.12
24-Stunden-Volumen:
38,327
Relative Volume:
0.21
Marktkapitalisierung:
$26.02M
Einnahmen:
$7.50M
Nettoeinkommen (Verlust:
$-9.85M
KGV:
-2.2568
EPS:
-1.3825
Netto-Cashflow:
$-24.56M
1W Leistung:
+3.65%
1M Leistung:
+5.76%
6M Leistung:
+0.32%
1J Leistung:
+15.77%
1-Tages-Spanne:
$3.06
$3.16
1-Wochen-Bereich:
$2.90
$3.1905
52-Wochen-Spanne:
$2.7094
$12.15
Evaxion A S Adr Stock (EVAX) Company Profile
Compare EVAX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
3.12 | 27.36M | 7.50M | -9.85M | -24.56M | -1.3825 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Maxim Group | Buy |
| 2024-04-02 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-02-12 | Eingeleitet | H.C. Wainwright | Buy |
Evaxion A S Adr Aktie (EVAX) Neueste Nachrichten
Evaxion Biotech Earnings Call: Data Strength, Cash Strain - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Evaxion Biotech A/S Adr (EVAX) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 - GlobeNewswire Inc.
European ADRs Rose As Biopharma Names Led The Pack - Finimize
US-Traded European Stocks Slipped As Arm And ArcelorMittal Fell - Finimize
Evaxion A/S Sponsored ADR Actuals & Estimates (NASDAQ:EVAX) - TradingView
European ADRs Edged Higher As Biotech Led Friday’s Moves - Finimize
Evaxion receives Prix Galien UK Award for Best digital health solution - Finansavisen
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia - Finansavisen
European ADRs Started The Week In The Green - Finimize
European ADRs Edged Higher In US Trading - Finimize
EVAXEvaxion A/S ADR Options - Finviz
Evaxion Biotech Signals Strong R&D Momentum Amid Cash Constraints - TipRanks
Most VolatileStock ScreenerNews - Finviz
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer - Finansavisen
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial - Finansavisen
Evaxion concludes Annual General Meeting - Finansavisen
Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 - Finansavisen
Endesa S.A. – Unsponsored ADR (OTCMKTS:ELEZY) Given Average Rating of “Strong Sell” by Brokerages - Defense World
Top GainersStock ScreenerSnapshot - Finviz
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
Notice to convene Evaxion’s Annual General Meeting - Finansavisen
Europe’s US-Listed ADRs Rose, Led By Solar And Biotech - Finimize
European ADRs Rose, While Biotech Names Did The Heavy Lifting - Finimize
Evaxion Biotech Earnings Call Highlights AI and Runway - TipRanks
Evaxion A/S (NASDAQ:EVAX) Receives Buy Rating from HC Wainwright - Defense World
Evaxion A/S (NASDAQ:EVAX) Price Target Cut to $9.00 by Analysts at Lake Street Capital - Defense World
Evaxion Earnings Report: Q4 Overview - Sahm
Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Up 20.9% in February - Defense World
Evaxion Biotech's Earnings: A Preview - Sahm
European ADRs Slip Slightly As Winners And Losers Split - Finimize
Evaxion Biotech’s Earnings Call Highlights Strategic Growth - TipRanks
European Biotech Stocks Outperformed As Broader Market Dipped - Finimize
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
Evaxion Stock Climbs Amid Biotech Surge - StocksToTrade
Evaxion Biotech A/S Announces Change in American Depositary Shares Ratio to Enhance Liquidity - nasdaq.com
Evaxion A/S (EVAX) Stock Forecast and Price Target 2026 - MarketBeat
Why Is Cancer Therapy Focused Evaxion Biotech Stock Trading Higher Today? - Sahm
Evaxion Biotech (EVAX) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - stocktwits.com
What is the current Price Target and Forecast for Evaxion A/SSponsored ADR (EVAX) - Zacks Investment Research
Top movers in Friday's pre-market session - ChartMill
Evaxion Biotech (EVAX) Stock Price Soared 236.9% Premarket Amid Buying Pressure - AskTraders
Finanzdaten der Evaxion A S Adr-Aktie (EVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):